Thera-SAbDab

TOCILIZUMAB

>   Structural Summary
TherapeuticTocilizumab
TargetIL6R
Heavy ChainQVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '22)Approved
Estimated Status (Aug '22)Active
Recorded Developmental Technologyna
INN Year Proposed2004
INN Year Recommended2004
Companies InvolvedAssistance Publique Hopitaux de Paris, Charite - Universitatsmedizin Berlin, Chugai Pharmaceutical, Hospital for Special Surgery, JW Pharmaceutical, Roche, University Hospital Inselspital, University Hospital, Osaka University Tubingen, University of Bern, University of Pittsburgh
Conditions ApprovedDrug hypersensitivity, Giant cell arteritis, Giant lymph node hyperplasia, Juvenile rheumatoid arthritis, Rheumatoid arthritis, Vasculitis
Conditions ActiveAdult-onset Still's disease, Osteoarthritis, Systemic scleroderma, Amyotrophic lateral sclerosis, Dermatomyositis, Familial Mediterranean fever, Polymyalgia rheumatica, Polymyositis, Pulmonary arterial hypertension, Schnitzler syndrome, Urogenital cancer
Conditions DiscontinuedChronic lymphocytic leukaemia, Ankylosing spondylitis, Crohn's disease, Multiple myeloma, Pancreatic cancer, Systemic lupus erythematosus
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy